Our understanding of COVID-19 has evolved greatly since its first appearance in the U.S. in early 2020. Though our knowledge remains incomplete, we’ve learned a lot about the pathophysiology of the virus—especially its unique effects on the heart.
As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.
Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?
To get the operational perspective, CVB hosted a roundtable discussion with service line leaders about the opportunities and challenges they encounter around data.
As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.
Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?
In this first magazine of the 2020s, CVB invites the cardiology community to consider new mindsets for a number of areas, from treating dementias to tackling authorizations, documentation and collections.
As healthcare strives to be everywhere for every patient, clinicians may be on the fast track to burnout. Here’s how some practices are dispersing their teams to achieve quality care, efficient workflows and satisfied clinicians.
